A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
Clinical trial NCT04935801 · COMPLETED
Trial details
- NCT number
- NCT04935801
- Sponsor
- Gylden Pharma Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-02
- Primary completion
- 2022-03-11
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.